```html

West African Sleeping Sickness (African Trypanosomiasis)

Overview

West African sleeping sickness, also called West African African trypanosomiasis or T. b. gambiense infection, is a parasitic disease caused by the protozoan Trypanosoma brucei gambiense. The parasite is transmitted to humans through the bite of an infected tsetse fly (Glossina spp.) that lives in the riverine and forested regions of sub‑Saharan Africa.

• Who it affects: Primarily people living in rural communities where tsetse flies thrive – often agricultural workers, hunters, and families in remote villages. Children and adults are equally susceptible.
• Geographic prevalence: The disease is endemic in 15 West‑Central African countries, including Senegal, Guinea, Côte d’Ivoire, Ghana, Nigeria, Cameroon, the Central African Republic, and the Democratic Republic of Congo. The World Health Organization (WHO) estimated ≈ 10,000 new cases worldwide in 2022, with > 95 % of those occurring in West and Central Africa.
• Public‑health impact: If untreated, the disease is fatal in up to 97 % of cases. Early detection dramatically improves outcomes, reducing mortality to below 5 %.

Symptoms

The clinical picture evolves in two stages. Early (hemolymphatic) stage lasts weeks to months, followed by a late (neurological) stage that can linger for years.

Early (Stage 1) – Hemolymphatic

• Fever or intermittent fever – often low‑grade, may mimic malaria.
• Headache – persistent, dull or throbbing.
• Generalised lymphadenopathy – especially in the posterior cervical chain (“Winterbottom’s sign”).
• Fatigue and malaise – profound tiredness despite rest.
• Muscle and joint aches – sometimes described as “arthralgia”.
• Loss of appetite, weight loss.
• Pruritus (itching) – often described as “skin itch”.
• Night sweats – profuse sweating that can disturb sleep.
• Localized skin changes – redness or a small ulcer at the bite site (rare).

Late (Stage 2) – Neurological

• Sleep disturbances – difficulty falling asleep at night and excessive daytime sleepiness (“somnolence”).
• Behavioural changes – irritability, confusion, or personality changes.
• Psychiatric symptoms – depression, anxiety, or psychosis.
• Encephalopathy – reduced consciousness, delirium, or coma.
• Motor dysfunction – tremor, gait instability, weakness, or loss of coordination.
• Sensory deficits – numbness, tingling, or loss of sensation in limbs.
• Seizures – reported in 5–10 % of late‑stage patients.
• Speech difficulties – slurred or slow speech (dysarthria).
• Vision problems – blurred vision, photophobia, or even optic neuritis.

Symptoms can vary widely; some patients progress slowly over years, while others deteriorate within months.

Causes and Risk Factors

What causes West African sleeping sickness?

The disease is caused by the subspecies Trypanosoma brucei gambiense. The parasite’s lifecycle includes:

1. Ingestion by tsetse fly: When a fly bites an infected animal (often humans in the case of T. b. gambiense) it ingests the bloodstream trypomastigotes.
2. Development in the fly: Parasites multiply and transform into the infectious metacyclic form in the fly’s salivary glands.
3. Transmission to humans: During a subsequent blood‑meal, the fly inoculates metacyclic trypomastigotes into the host’s skin.
4. Human infection: Parasites multiply in the subcutaneous tissue, spread to the bloodstream and lymphatic system (stage 1), then cross the blood‑brain barrier (stage 2).

Risk factors

• Geographic exposure – Living, working, or traveling in endemic rural zones.
• Occupational exposure – Farming, fishing, logging, or hunting in tsetse‑fly habitats.
• Poor housing – Homes without screens or insecticide‑treated nets.
• Limited access to health care – Delays in diagnosis increase risk of progression.
• Age – Children and the elderly may develop severe disease more rapidly because of weaker immunity.

Diagnosis

Diagnosis combines clinical suspicion with laboratory confirmation. Early detection is essential because stage‑2 treatment is more toxic.

Clinical assessment

• History of exposure to tsetse‑fly regions.
• Identification of stage‑1 signs (fever, lymphadenopathy) or stage‑2 neuro‑psychiatric manifestations.

Laboratory tests

1. Microscopy – Thick or thin blood smears stained with Giemsa; direct visualization of trypanosomes in blood, lymph node aspirate, or cerebrospinal fluid (CSF).
2. Serology – Card Agglutination Test for Trypanosomiasis (CATT) is widely used for screening; high sensitivity (≈95 %).
3. Polymerase Chain Reaction (PCR) – Detects parasite DNA in blood, CSF, or tissue; useful when microscopy is negative.
4. Lumbar puncture – Critical for staging. CSF is examined for:
   • Presence of trypanosomes.
   • White‑blood‑cell count > 5 cells/µL suggests CNS involvement.
   • Elevated protein levels.
5. Imaging (optional) – MRI or CT may show brain inflammation, but are not diagnostic.

Reference: CDC – Diagnosis of Human African Trypanosomiasis.

Treatment Options

Treatment depends on disease stage.

Stage 1 (Hemolymphatic)

• Pentamidine isethionate (Benoit’s drug): 4 mg/kg IV/IM once daily for 10 days. Effective in > 95 % of cases, with mild side effects (nausea, low blood pressure).
• Suramin (alternative where pentamidine is contraindicated): 20 mg/kg IV on days 1, 3, 5, 7, 9, 14, 21, 28. Requires renal monitoring.

Stage 2 (Neurological)

Because the parasite has crossed the blood‑brain barrier, drugs must penetrate the CNS.

• Eflornithine (DFMO): 100 mg/kg IV every 6 hours for 14 days. Often called “the safe drug” due to low toxicity.
• Nifurtimox‑Eflornithine Combination Therapy (NECT): Eflornithine 400 mg/kg IV every 12 hours plus oral nifurtimox 15 mg/kg/day for 10 days. NECT shortens hospital stay and reduces side‑effects.
• Melarsoprol (arsenic‑based): Reserved for rare cases where eflornithine is unavailable. Highly neurotoxic; can cause a fatal reactive encephalopathy in 5–10 % of patients.

Supportive care

• Hydration and electrolyte management.
• Antipyretics for fever.
• Anticonvulsants (e.g., levetiracetam) if seizures occur.
• Psychiatric support for mood or psychotic symptoms.

All treatments should be administered under medical supervision, preferably in an accredited treatment centre. The WHO’s “Guidelines for the treatment of human African trypanosomiasis” (2022) provide detailed dosing charts.

Living with West African Sleeping Sickness

Even after successful therapy, patients may face residual symptoms and need ongoing care.

• Follow‑up appointments – CSF examination is repeated 6 months after treatment to ensure parasite clearance.
• Rehabilitation – Physical therapy can improve gait, strength, and coordination deficits.
• Neuro‑cognitive monitoring – Memory, attention, and mood should be screened periodically; refer to neuro‑psychology if deficits persist.
• Nutrition – Balanced diet rich in protein aids immune recovery; address anemia with iron‑rich foods or supplements.
• Medication adherence – Complete the full drug course; missing doses can lead to relapse or drug resistance.
• Community support – Engage local health workers or patient support groups for education and emotional encouragement.

Prevention

Because the disease is vector‑borne, prevention focuses on reducing fly contact.

Personal protective measures

• Wear long‑sleeved shirts and trousers, preferably treated with permethrin.
• Use insecticide‑treated bed nets (ITNs) during the day and night when flies are active.
• Apply DEET‑based repellents to exposed skin.
• Avoid high‑risk areas (river banks, dense forest) during peak tsetse activity (dawn and dusk).

Environmental strategies

• Clear vegetation around homes and livestock pens to reduce fly resting sites.
• Use traps or insecticide‑treated targets (blue/black cloth) to reduce local tsetse populations.
• Coordinate with national vector‑control programs for aerial spraying where appropriate.

Community‑level interventions

• Mass screening using CATT in endemic villages; treat positives promptly.
• Health‑education campaigns that teach recognition of early symptoms.
• Strengthen referral pathways so suspected cases reach diagnostic centres quickly.

Complications

If left untreated, West African sleeping sickness can lead to severe, often irreversible, complications:

• Neurological damage – Permanent cognitive impairment, motor dysfunction, or paralysis.
• Psychiatric illness – Chronic depression or psychosis.
• Cardiac arrhythmias – Reported in late‑stage disease due to autonomic dysfunction.
• Renal failure – May result from prolonged dehydration and drug toxicity.
• Secondary infections – Due to immunosuppression and malnutrition.
• Death – Mortality approaches 100 % without therapy.

When to Seek Emergency Care

Key Take‑aways

• West African sleeping sickness is curable when diagnosed early; however, it remains fatal without treatment.
• Symptoms start with nonspecific fever and lymphadenopathy, later progressing to sleep disruption and neurological signs.
• Diagnosis relies on a combination of clinical suspicion, serology (CATT), microscopy, PCR, and CSF analysis.
• Stage‑specific therapy (pentamidine or suramin for stage 1; eflornithine or NECT for stage 2) is highly effective.
• Prevention centers on vector control, personal protection, and community screening.

For the most current guidelines, visit the WHO Human African Trypanosomiasis page and consult local health authorities.

```